secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001140361-25-040104
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys gets FDA IDE approval for FemBloc final trial phase, secures $12M financing
--------------------------------------------------------------------------------

- FDA IDE approval to continue enrollment in Part B of FINALE pivotal trial for FemBloc non-surgical permanent birth control.
- $12M senior secured convertible notes issued with potential total proceeds of $58M if all warrants exercised.
- Notes bear 8.5% interest, 10-year maturity, convertible at $0.73/share (15% premium to last close).
- Warrants issued at exercise prices of $0.81, $0.92, and $1.10 per share, each for 16.4M shares.
- Proceeds to refinance debt and advance commercialization of fertility and birth control portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125040104/0001140361-25-040104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125040104/ef20058162_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-040104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer